Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple nudge: mailed reminders and navigators may catch liver cancer earlier

NCT ID NCT06635694

Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether sending mailed invitations and assigning patient navigators can increase the number of high-risk patients who attend regular liver cancer ultrasound screenings. The trial includes 652 adults with cirrhosis or chronic hepatitis B, who are at risk for hepatocellular carcinoma. The goal is to see if these simple support tools help catch liver cancer at an earlier, more treatable stage compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that simple support like mailed reminders and a navigator can help more high-risk patients get regular liver cancer screening, potentially catching cancer earlier.
What could go wrong
This is a behavioral study, not a drug trial. Even if attendance improves, it may not lead to earlier cancer detection or better survival. Results may not apply to all healthcare settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

652 people

The number who actually took part.

Started

Feb 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients receiving 6-monthly ultrasound surveillance for HCC

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18 years of age or older * ECOG performance status of 0-2 * Eligible for HCC surveillance as defined by NICE and EASL criteria * Child Pugh A or B cirrhosis * Child Pugh C cirrhosis AND on liver transplant waiting list * High risk chronic hepatitis B Exclusion Criteria: * Previous or current diagnosis of HCC * Child Pugh C cirrhosis * Frailty (Clinical Frailty Scale \>7) * Previous liver transplant

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hep B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection cirrhosis of liver hepatitis B virus infection hepatocellular carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hep B Hepatocellular carcinoma Liver cirrhosis

Contacts and locations

Locations

  • Imperial College Healthcare NHS Trust

    London, W12 0HS, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.